Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5816179 | 0.90 | KMT2A (0.68) | ALDH1A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL4873292 | 0.83 | KMT2A (1.00) | ALDH1A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL12247551 | 0.81 | ALDH1A1 (0.78) | ALDH1A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL29201430 | 0.81 | ALDH1A1 (0.82) | ALDH1A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL4872274 | 0.81 | KMT2A (0.68) | ALDH1A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL17950740 | 0.81 | MEN1 (0.68) | ALDH1A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL10919578 | 0.81 | KMT2A (0.82) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL1845784 | 0.80 | KMT2A (0.70) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL28844026 | 0.80 | KMT2A (0.66) | ALDH1A1MEN1KMT2AHTTNPC1 | |
| SCHEMBL8878218 | 0.79 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2AHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108276352-B | Nitrogen-containing heterocyclic compound with nematicidal activity and preparation method and application thereof | 华东理工大学 | 2022-09-20 | — | — | CN | disclosed |
| US-8710261-B2 | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases | RANBAXY LABORATORIES LIMITED (IN) | 2014-04-29 | — | — | US | disclosed |
| EP-1856063-B1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LAB LTD (IN) | 2012-01-25 | — | — | EP | disclosed |
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-08-14 | — | — | US | disclosed |
| EP-1856063-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | Ranbaxy Laboratories Limited (IN) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006090235-A1 | 5-PHENYL-PENTANOIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FOR THE TREATMENT OF ASTHMA AND OTHER DISEASES | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194565-A1 | 5-Phenyl-Pentanoic Acid Derivatives as Matrix Metalloproteinase Inhibitors for the Treatment of Asthma and Other Diseases | F2RL3, ACOX3, LPAR5 | ALDH1A1 2132/4885MEN1 4633/4885KMT2A 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.